Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,638,910 new cancer cases and 577,190 deaths from cancer are projected to occur in the United States in 2012. During the most recent 5 years for which there are data (2004)(2005)(2006)(2007)(2008), overall cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.6% per year in women. Over the past 10 years of available data (1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008), cancer death rates have declined by more than 1% per year in men and women of every racial/ethnic group with the exception of American Indians/Alaska Natives, among whom rates have remained stable. The most rapid declines in death rates occurred among African American and Hispanic men (2.4% and 2.3% per year, respectively). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate), with lung cancer accounting for almost 40% of the total decline in men and breast cancer accounting for 34% of the total decline in women. The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 1,024,400 deaths from cancer. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket. CA Cancer J Clin 2012;00:000-000.
Introduction
Cancer is a major public health problem in the United States and many other parts of the world. One in 4 deaths in the United States is due to cancer. In this article, we provide the expected numbers of new cancer cases and deaths in 2012 nationally and by state, as well as an overview of current cancer statistics using data through 2008, including incidence, mortality, and survival rates and trends. We also estimate the total number of deaths averted as a result of the decline in cancer death rates since the early 1990s, and provide the reported number of cancer deaths in 2008 by age for the 5 leading cancer types.
Materials and Methods

Incidence and Mortality Data
Mortality data from 1930 to 2008 in the United States were obtained from the National Center for Health Statistics (NCHS).
1,2 There are several sources for cancer incidence data. The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute reports long-term (beginning in 1973), highquality, population-based incidence data covering up to 26% of the US population. Cancer incidence rates for long-term trends , 5-year relative survival rates (2001) (2002) (2003) (2004) (2005) (2006) (2007) , and estimations of the lifetime ‡  350  110  120  460  130  160  530  170  Ohio  472.4  66,560  8,990  400  6,020 2,110  1,810  10,270  3,030  2,920  8,560 3,160  Oklahoma  483.9  19,210  2,630  170  1,780  470  600  3,370  750  850  2,560  820  Oregon  473.3  21,370  3,200  130  1,670  620  610  2,920  1,290  950  3,460 1,020  Pennsylvania  503.9  78,340 10,290  460  7,330 2,570  2,340  10,890  3,470  3,510 8, 9 Cancer cases were classified according to the International Classification of Diseases for Oncology. 10 All incidence and death rates are age-standardized to the 2000 US standard population and expressed per 100,000 persons.
Cancer incidence rates in this report are delayadjusted whenever possible in order to account for anticipated future corrections to registry data due to inherent delays and errors in case reporting. Delayadjusted rates primarily affect the most recent years of data for cancers that are frequently diagnosed in outpatient settings (eg, melanoma, leukemia, and prostate) and provide a more accurate portrayal of the cancer burden in the most recent time period.
11 Delayadjusted rates are available for SEER registry data and were obtained from the National Cancer Institute. 12 
Projected Cancer Cases and Deaths in 2012
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because cancer registration is incomplete in some states. Note: State estimates may not add to US total due to rounding and the exclusion of states with fewer than 50 deaths.
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Furthermore, the most recent year for which incidence and mortality data are available lags 3 to 4 years behind the current year due to the time required for data collection, compilation, and dissemination. Therefore, we project the numbers of new cancer cases and deaths in the United States in 2012 in order to provide an estimate of the contemporary cancer burden. The methods for projecting both new cases and deaths in 2012 have been modified, so these estimates should not be compared with those from previous years. We projected the numbers of new malignant cancer cases that will be diagnosed in 2012 using a 2-step process that first estimates complete incidence counts by state during years for which observed data are available, and then projects these counts 4 years ahead for the United States overall and each state individually. 13 To obtain estimated counts for each state through 2008, we used a spatiotemporal model based on incidence data from 1995 through 2008 for 47 states and the District of Columbia that met NAACCR's highquality data standard for incidence, covering about 95% of the US population.
14 This method accounts for expected delays in case reporting and considers geographic variations in sociodemographic and lifestyle factors, medical settings, and cancer screening behaviors as predictors of incidence. A temporal projection method (the vector autoregressive model) was then applied to the estimated counts to obtain the 2012 projections. For the complete details of this methodology, please refer to Zhu et al. 13 To estimate the numbers of new breast carcinoma in situ (female) and melanoma in situ cases in 2012, we first estimated the number of in situ cases occurring annually from 2000 through 2008 in the United States by applying the age-specific incidence rates in the 17 SEER areas to the corresponding US population estimates. 3, 15 We then projected the total number of cases in 2012 based on the annual percent change from 2000 through 2008 generated by the joinpoint regression model. 16 We estimated the number of cancer deaths expected to occur in 2012 in the United States overall and in each state using the joinpoint regression model based on the actual number of cancer deaths from 1994 through 2008 at the state and national levels as reported to the NCHS. 2, 17 For the complete details of this methodology, please refer to Chen et al. 17 
Other Statistics
The estimated numbers of cancer deaths averted in men and women due to the reduction in overall cancer death rates were calculated by applying the 5-year age-specific cancer death rates in the peak year for age-standardized cancer death rates (1990 in men and 1991 in women) to the corresponding Cancer Statistics, 2012 age-specific populations in subsequent years through 2008 to obtain the number of expected deaths in each calendar year if the death rates had not decreased. We then summed the difference between the numbers of expected and observed deaths in each age group and calendar year for men and women separately.
Selected Findings
Expected Numbers of New Cancer Cases Table 2 . Figure 1 indicates the most common cancers expected to occur in men and women in 2012. Among men, cancers of the prostate, lung and bronchus, and colorectum will account for about half of all newly diagnosed cancers; prostate cancer alone will account for 29% (241,740) of incident cases. The 3 most commonly diagnosed types of cancer among women in 2012 will be breast, lung and bronchus, and colorectum, accounting for about half of the estimated cancer cases in women. Breast cancer alone is expected to account for 29% (226,870) of all new cancer cases among women. Table 1 also shows the expected numbers of deaths from cancer projected for 2012. It is estimated that 577,190 Americans will die from cancer this year, corresponding to more than 1,500 deaths per day. Cancers of the lung and bronchus, prostate, and colorectum in men and cancers of the lung and bronchus, breast, and colorectum in women continue to be the most common causes of cancer death. These 4 cancers account for almost half of the total cancer deaths among men and women (Fig. 1) . In 2012, lung cancer is expected to account for 26% of all female cancer deaths and 29% of all male cancer deaths. Table  3 provides the estimated numbers of cancer deaths in 2012 by state for selected cancers.
Expected Numbers of Cancer Deaths
Lifetime Probability of Developing Cancer
The lifetime probability of being diagnosed with an invasive cancer is higher for men (45%) than for women (38%) ( Table 4) . However, because of the earlier median age at diagnosis for breast cancer compared with other major cancers, women have a slightly higher probability of developing cancer before age 60 years. These estimates are based on the average experience of the general population and may over-or underestimate individual risk because of differences in exposure (eg, smoking history) and/ or genetic susceptibility.
Trends in Cancer Incidence
Figures 2 to 5 depict long-term trends in cancer incidence and death rates for all cancers combined and for selected cancers by sex. Table 5 shows incidence (delay-adjusted) and mortality trends for all cancers combined and for the 4 most common cancer sites based on joinpoint regression analysis. Joinpoint is a tool used to describe and quantify trends by fitting observed rates to lines connected at ''joinpoints'' where trends change in direction or magnitude. 16 According to data from the SEER 13 cancer registries, incidence rates in the most recent 5 years (2004-2008) decreased in males by 0.6% per year and were stable in females (Table 5) . Incidence rates decreased for all 4 major cancer sites except the female breast, for which rates remained relatively stable from 2005 to 2008 after decreasing by 2% per year from 1999 to 2005. Lung cancer incidence rates in women began declining in the late 1990s, more than a decade after the decline began in men. 6 Differences in lung cancer incidence patterns between men and women (Fig. 3 ) reflect historical differences in tobacco use; cigarette smoking prevalence peaked about 20 years later in women than in men. 19 Recent rapid declines in colorectal cancer incidence rates have largely been attributed to increases in screening that can detect and remove precancerous polyps. [20] [21] [22] Although joinpoint trend analysis shows that the incidence rate for prostate cancer declined steadily by 1.9% per year from 2000 to 2008, it is important to realize that annual rates fluctuate widely from year to year (Fig. 3) , likely reflecting variation in the prevalence of prostate-specific antigen testing for the detection of prostate cancer. For example, in the SEER 13 areas, the delay-adjusted prostate cancer incidence rate increased from 152. Rates are age adjusted to the 2000 US standard population. Due to changes in International Classification of Diseases (ICD) coding, numerator information has changed over time. Rates for cancers of the uterus, ovary, lung and bronchus, and colorectum are affected by these changes. *Uterus includes uterine cervix and uterine corpus.
CA CANCER J CLIN 2012;00:000-000 VOLUME 00 _ NUMBER 0 _ MONTH/MONTH 2012 breast, and prostate (Figs. 4 and 5 ). Among men, reductions in death rates for lung, prostate, and colorectal cancers account for 78% of the total decrease in the cancer death rate, with lung cancer alone accounting for almost 40% of the decrease. Among women, reductions in death rates for breast and colorectal cancers account for 56% of the total decrease, with breast cancer accounting for 34% of the decrease in women. The decrease in lung cancer death rates among men since 1990 is due to the reduction in tobacco use over the past 50 years, 23 while the decrease in death rates for female breast, colorectal, and prostate cancer largely reflects improvements in early detection and/or treatment. 
Recorded Number of Deaths From Cancer in 2008
A total of 565,469 cancer deaths were recorded in the United States in 2008, the most recent year for which actual data are available. Cancer is the second leading cause of death following heart disease, accounting for 23% of all deaths. From 2007 to 2008, the age-standardized cancer death rate decreased 1.5%, from 178.4 (per 100,000) to 175.8. Table 6 presents the numbers of deaths from all cancers combined and from the 5 most common cancer types for each 20-year age group. Leukemia is the most common cause of cancer death among males aged younger than 40 years, while lung cancer ranks first among those aged 40 years and older. Among females, leukemia is the leading cause of cancer death among children and adolescents (those aged younger than 20 years), breast cancer ranks first among women ages 20 to 59 years, and lung cancer causes the most cancer deaths in those aged 60 years and older.
Regional Variations in Cancer Rates
Tables 7 and 8 depict cancer incidence and death rates for selected cancers by state. Lung cancer shows the largest geographic variation in cancer occurrence by far, reflecting the large historical and continuing differences in smoking prevalence among states. 23 For example, lung cancer incidence rates in Kentucky, which has highest smoking prevalence, are almost 4-fold higher than those in Utah, which has the lowest smoking prevalence. In contrast, state variations for other cancer sites are smaller in both absolute and proportionate terms. For example, the breast cancer incidence rate in Connecticut, which has the highest rate (136.2 per 100,000), is only 28% higher than that in Arizona, which has the lowest rate (106.7 per 100,000). For cancers that can be detected by screening or other testing practices, such as those of the prostate, female breast, and colorectum, state variation in incidence rates reflects differences in the use of screening tests or detection practices in addition to differences in disease occurrence.
Cancer Occurrence by Race/Ethnicity
Cancer incidence and death rates vary considerably among racial and ethnic groups ( Table 9 ). For all cancer sites combined, African American men have a CA CANCER J CLIN 2012;00:000-000 VOLUME 00 _ NUMBER 0 _ MONTH/MONTH 2012 15% higher incidence rate and a 33% higher death rate than white men, whereas African American women have a 6% lower incidence rate but a 16% higher death rate than white women. For the specific cancer sites listed in Table 9 , incidence and death rates are consistently higher in African Americans than in whites except for cancers of the breast (incidence) and lung (incidence and mortality) among women, and kidney (mortality) among both men and women. Factors known to contribute to racial disparities in mortality vary by cancer site and include differences in exposure to underlying risk factors (eg, historical smoking prevalence for lung cancer), access to high-quality screening (breast, cervical, and colorectal cancers), and timely diagnosis and treatment for many cancers. 26 The higher breast cancer incidence rate noted among white women is thought to reflect a combination of factors that affect both diagnosis (more prevalent mammography use in white women) and underlying disease occurrence (increased prevalence of risk factors in white women, such as later age at first birth and greater use of menopausal hormone therapy). 27 Cancer incidence and death rates are lower in other racial and ethnic groups than in whites and African Americans for all cancer sites combined and for the 4 most common cancer sites. However, incidence and death rates for cancers related to infectious agents, such as those of the uterine cervix, stomach, and liver, are generally higher in minority populations than in whites. Stomach and liver cancer incidence and death rates are twice as high in Asian Americans/Pacific Islanders as in whites, reflecting an increased prevalence of chronic infection with Helicobacter pylori and hepatitis B and C viruses in this population. 28 Kidney cancer incidence Rates are per 100,000 and age adjusted to the 2000 US standard population. and death rates are the highest among American Indians/Alaska Natives; the higher prevalence of obesity and smoking in this population may contribute to this disparity. 29 Cancer incidence rates can only be adjusted for delayed reporting in whites and African Americans because the long-term incidence data required for delay adjustment are not available for other racial and Rates are per 100,000 and age adjusted to the 2000 US standard population.
ethnic groups. During the past 10 years of data (1999-2008), while incidence rates (unadjusted for delayed reporting) declined by 1% or more per year among men of all racial/ethnic groups, among women only slight declines (0.4% per year) occurred in whites and Hispanics (Table 10 ). In contrast, cancer death rates declined by 1% or more per year among men and women of all races/ethnicities except American Indians/Alaska Natives, among whom rates remained stable. Notably, the largest declines in death rates occurred among men of African American (2.4% per year) and Hispanic (2.3% per year) heritage. 7) . These disparities may result from inequalities in access to and receipt of quality health care and/or from differences in comorbidities. As shown in Figure 8 , African Americans are less likely than whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated. The extent to which factors other than stage at diagnosis contribute to the overall survival differential is unclear. 30 However, some studies suggest that African Americans who receive cancer treatment and medical care similar to that of whites experience similar outcomes. 31 There have been notable improvements since 1975 in the relative 5-year survival rates for most cancers for both whites and African Americans (Table 11) . Increases in survival rates over time reflect a combination of earlier diagnosis and improvements in treatment. Cancers of the lung and pancreas have shown little improvement in survival over the past 30 years.
Relative survival rates cannot be calculated for some minority populations because accurate life expectancies are not available. However, based on cause-specific survival rates of cancer patients diagnosed from 2001 to 2007 in SEER areas of the United States, all minority male populations have a greater probability of dying from cancer within 5 years of diagnosis than whites. 6 Among women, African Americans have the lowest 5-year cancer-specific survival, followed by American Indians/Alaska Natives, Hispanics, whites, and Asian Americans/Pacific Islanders. 6 For all 4 major cancer sites (prostate, female breast, lung and bronchus, and colorectum), minority populations are generally more likely than non-Hispanic whites to be diagnosed at a distant stage of disease. 32 
Cancer in Children
Cancer is the second most common cause of death among children ages 1 to 14 years in the United States, surpassed only by accidents; 1,284 children died from cancer in 2008. Leukemia accounts for one-third of all cancers diagnosed in children (ages 0 to 14 years), 78% of which are acute lymphocytic leukemias. 6 Cancers of the brain and other nervous system are the second most common cancer type (27%), followed by soft tissue sarcomas (7%, half of which are rhabdomyosarcoma), neuroblastoma (7%), renal (Wilms) tumors (5%), and Hodgkin and nonHodgkin lymphomas (4% each). 6 From 2004 to 2008, the overall incidence rate for cancer in children aged 14 years and younger increased slightly by 0.5% per year, a trend that has been consistent since 1975. The death rate for childhood cancer has decreased by more than half over the past 3 decades, from 4.9 (per 100,000) in 1975 to 2.2 in 2008.
2 Table 12 provides trends in survival rates for the most common childhood cancers. The 5-year relative survival rate for all cancers combined improved from 58% for children diagnosed between 1975 and 1977 to 83% for those diagnosed between 2001 and 2007. 6 The substantial progress for all of the major childhood cancers reflects both improvements in treatment and high levels of participation in clinical trials. 
Limitations
The projected numbers of new cancer cases and cancer deaths should be interpreted cautiously because these estimates are model-based and may vary considerably from year to year for reasons other than changes in cancer occurrence. For instance, estimates are invariably affected by changes in method, which occur regularly as modeling techniques improve over time and cancer registration becomes more complete. Indeed, new methods were used for projecting both incident cases and deaths in 2012. In addition, not all changes in cancer trends *The standard error of the survival rate is between 5 and 10 percentage points. †The survival rate for carcinoma in situ of the urinary bladder is 97% for All Races and Whites and 92% for African Americans.
CA CANCER J CLIN 2012;00:000-000 VOLUME 00 _ NUMBER 0 _ MONTH/MONTH 2012 can be captured by modeling techniques. For these reasons, we discourage the use of these estimates to track year-to-year changes in cancer occurrence and death. The data sources used for tracking cancer trends are age-standardized or age-specific cancer death rates from the NCHS and cancer incidence rates from SEER or NPCR. Nevertheless, the American Cancer Society projections of the numbers of new cancer cases and deaths provide a reasonably accurate estimate of the current cancer burden in the United States. Errors in reporting race/ethnicity in medical records and on death certificates may result in underestimates of cancer incidence and mortality rates in nonwhite *The proportions of carcinoma in situ of the urinary bladder are 51%, 51%, and 38% in All Races, Whites, and African Americans, respectively. Stage categories do not sum to 100% because sufficient information is not available to assign a stage to all cancer cases. and non-African American populations. It is also important to note that cancer data in the United States are primarily reported for broad racial and ethnic minority groups that are not homogenous, and thus important differences in the cancer burden within racial/ethnic subgroups are often masked. n 
